Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Robert John Motzer, Thomas E. Hutson, Piotr Tomczak, Marc Dror Michaelson, Ronald M. Bukowski, Olivier Rixe, Stéphane Marie. Oudard, Sylvie Négrier, Cezary A. Szczylik, Sindy T. Kim, Isan Chen, Paul W. Bycott, Charles M. Baum, Robert A. Figlin
New England Journal of Medicine · 2007 · 5,822 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S. M., Négrier, S., Szczylik, C. A., Kim, S. T., Chen, I., Bycott, P. W., Baum, C. M., & Figlin, R. A. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine, 356(2), 115–124. https://doi.org/10.1056/nejmoa065044
In text: (Motzer et al., 2007)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
BACKGROUND: Since sunitinib malate has shown activity in two uncontrolled studies in patients with metastatic renal-cell carcinoma, a comparison of the drug with interferon alfa in a phase 3 trial is warranted. METHODS: We enrolled 750 patients with previously untreated, metastatic renal-cell carcinoma in a multicenter, randomized, phase 3 trial to receive either repeated 6-week cycles of sunitinib (at a dose of 50 mg given orally once daily for 4 weeks, followed by 2 weeks without treatment) or interferon alfa (at a dose of 9 MU given subcutaneously three times weekly). The primary end point was progression-free survival. Secondary end points included the objective response rate, overall survival, patient-reported outcomes, and safety. RESULTS: The median progression-free survival was significantly longer in the sunitinib group (11 months) than in the interferon alfa group (5 months), corresponding to a hazard ratio of 0.42 (95% confidence interval, 0.32 to 0.54; P<0.001). Sunitinib was also associated with a higher objective response rate than was interferon alfa (31% vs. 6%, P<0.001). The proportion of patients with grade 3 or 4 treatment-related fatigue was significantly higher in the group treated with interferon alfa, whereas diarrhea was more frequent in the sunitinib group (P<0.05). Patients in the sunitinib group reported a significantly better quality of life than did patients in the interferon alfa group (P<0.001). CONCLUSIONS: Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa (ClinicalTrials.gov numbers, NCT00098657 and NCT00083889 [ClinicalTrials.gov]).
Related papers
- Sorafenib in Advanced Hepatocellular Carcinoma2008
- Preoperative assessment of liver function: a comparison of 99mTc‐Mebrofenin scintigraphy with indocyanine green clearance test2004
- Management of Hepatocellular Carcinoma: An Update Δσ2011
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma2020
- Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis1996
Metadata from OpenAlex (CC0). Citations are generated from the published record.